
Remote Accessibility to Diabetes Management and Therapy in Operational Healthcare Networks





Research Question

To investigate the feasibility of using the REACTION Platform including remote monitoring, patient education and Risk Stratification to improve clinical outcomes and patient self-management for a diabetes population in primary care

•The REACTION platform enables collection of data from both remote monitoring equipment, patient input data via the patient portal and manual entry of data extracted from the EPR to create a comprehensive diabetes data management system

•Outputs allow for risk stratification to identify patients in the greatest need of medical intervention and provide educational feedback to support patient self-management



Aim

•The aim of the study is to investigate whether improvements could be made in clinical outcomes, patient compliance and self-management, and patient/clinician satisfaction through an assessment and intervention program

The objectives of the study are to

1. Improve professional compliance by following defined Map of Medicine and NICE guidelines to identify and target interventions

2.Improve patient outcomes as measured by HbA1c, Cholesterol, home blood pressure and home blood glucose measurements

3. Improve patient understanding and compliance with therapeutic regimes

4. Measure patient and clinical perception and satisfaction



• Clinical Pre-Pilot – Sep 2012

• Clinical Pilot – Jan 2013

- -Home Physiological Measurements
- -Activity/Diet Data
- -Compliance Data
- -Risk Stratification
- Interim Evaluation June 2012

• Long Term Risk Sep 2012 – 2013

-Data Extraction for type 1 and type 2

-Validation of models

• Short Term Risk Dec 2013

- –Pattern Management
- -Semantic Search
- ePatch ECG
 - –Pre-Pilot May 2013

-Pilot - Oct 2013




- Friends and family testing involved users that were not from the target population, they included researchers, friends and neighbours of those working within the study. 3 participants
- Field Testing involved patients from the target sample 7 participants

Objectives

- Test reliability and robustness in a non-lab environment
- Test functionality of the equipment in a non-lab environment
- Test usability and functionality of patient portal
- Test usability and functionality of clinical portal
- Receive usability feedback
- Train clinical users on equipment and clinical interface
- Refine monitoring and clinical protocols


Pilot Phase – Jan 2013 Sample

Patient Selection. All patients on the diabetes register are eligible to be included





NICE Workflow




Activity

Clinic Tests Monitoring data Diet Data Activity Data Medication Data

Shared via the patient portal

Review Long Term Risk Short Term Risk

Clinical Action Referral Patient Self Management





- Patients invited to take part at 6 month and 12 month appointments – offered as usual service
- Administrative support for enrolment/training is given by a non clinical care assistant
- Patients are seen by the diabetes nurse for 1st review visit 30 min appt
- Patients seen by GP for follow up review 10 min appt
 - Review Remote Monitoring Data
 - Record outcome on EPR
- Risk stratification is completed through review by GP
- Interventions are conducted by Nurse and GP

Protocol – Review Visit 1 - Revised

- Appt times increased to 30 minutes
- Usual clinic tests taken
- Patient is enrolled onto the program
- Above carried out by nurse



Protocol – Review Visit 1 - Revised

- Patients instructed in the self monitoring of blood glucose and blood pressure
- Given monitoring plan
- Given access to patient portal
- Above carried out by non clinician immediately after appointment



Protocol – Home Monitoring

- Patient asked to self monitor fasting Blood Glucose and Blood Pressure for 14 days
- Complete activity Self assessment
- Complete diet Self assessment
- Complete medication compliance
- Given access to patient portal

Monitoring Plan

Policin, Name.	
Date boucd	
iccued by	
Date to be Reviewed	

Physiological Measurements

Device	Frequency	Time	Pre / Post Prandial	Duration
Blood Glucos		Breakfast Lunch Dinner Before Bed		
Bland Pressu				
8		15	E.	- K

Patient Portal

User Name Password

Action	Frequency	Time	Duration
Diet Self-			
Assessment			
Activity Self -			
Assessment			
Medication Self-			
Assessment			

Action Daily Medication	Prequency	Time	Duration
Insulin Dose		1	
Carbs		34	

@ Protocol – Clinical Monitoring

- Patients are monitored for missing data or extreme values during the 2 weeks by non clinical staff
- Risk profiles are generated using risk engines (UKPDS) and clinical guidelines
- Results are reviewed by GP and Nurse
- Patients are stratified into High, Medium and Low Risk groups
- Interventions are planned


Q Protocol – Risk Stratification Model

Risk Factor	Low	Medium	High	
HbA1c	<7%	7-8%	>8%	
Total Cholesterol	<4 mmol/L	4-5 mmol/L	>5 mmol/L	
LDL	<2 mmol/L	2-3 mmol/L	>3 mmol/L	
HDL	>1	0.9 - 1	<1	
Blood Pressure	<140/80 <130/70 Renal	140-150/80-85	>150/85	
Fasting Blood Glucose	<7	7-10 mmol/L	>10 mmol/L	
History				
Renal – EGFR >90 age N/A	CKD1 60-89 mL/min	CKD2 30-59 mL/min	CKD3 15-29 mL/min	CKD4 <15 mL/min
Creatinine - Male	<110 µmol/L	<150 µmol/L	>150 µmol/L	
Creatinine - Female	<92 µmol/L	<150 µmol/L	>150 µmol/L	
CVD – Amputation	, Medium to high fo	ot risk, history of at	rial fibrillation or Str	oke (CVA)
	or Stent/CABG (hea	rt surgery)		

CHD – UKPDS , MI or Stent/CABG (heart surgery)

Protocol – Review follow up

- Patient results are shared and discussed with the patient
- Care Plan agreed and shared either via the patient portal or paper
- Intervention takes place if necessary





Intervention	Reaction Tool Kit
 Decision on Therapy – Lifestyle Referral to self management courses Diabetes Education Dietician Activity 	Diet Self Assessment Activity Self Assessment Education Recording Carb Intake
Decision on Therapy – Blood Glucose Control	Blood Glucose Monitoring
Decision on Therapy – Oral Therapy	Blood Glucose Monitoring Medication Compliance
Insulin Therapy	Blood Glucose Monitoring Insulin Diary
Complications/RISK Cardiovascular Team Renal Team Ophthalmology Vascular Surgeon Neurologist Obs Gynae – pregnant patients only 	Monitoring of Co-morbidities: •Blood Pressure •Weight •SpO2 •Step Up Patients • Video Conferencing

Managing Patient Information Clinical Portal

Hore	Add New	Device			- Martin	- U.A M
en.e	from B		- Pettern	Stel (et align	And a Design (in the second	Sá/Sáya
All ten Went	Crice	_	Sine and	111	200	
Al Paderta	an trans	S100		2		
ale:	Device M	aragement:				
kfske	Search by::	Hall Lovero Denke ((X.P.J.:1.Xe :	-	
lavarrent.	UN EN IN	anda Textuliya	Georgian	a Roet	Tale	Downed M
14.27		Just Net2	1	10.000	N. Garal	0000 20
362		Start Mict		Articidos:	101101	HEAS - MA
864		Separation		M insthe Byeld		2073XI 10
		Sate No.			N. Oural	210302
		marin			Riburk	20.00 m
bild		300 000	8	Technie (Horse)		10082
lonesege		756-01			in the of	34441 Int
10		210.07			w.usaf	ISAN: ON
		-18/2508			BULLYON .	nor w
(de Heiz Poer	Exton		AUX I	netr W.L.	The second	COLUMN STREET
21228 th		RY		2		
10000000000		0me	live	Marzee (mod/L)	lype	Collected
h s		CARGINS.	-1.0	-1	- Olive	CATE AND
het also	-	234362212	:350	15	0.8	188
	100	Doladi.	138	20	VER	28.8
La ren	1000	1419017	39	52	ing.	197.81
2610232	-	ISPORT.	10.15	71	Q1.8	Te.te:
Exc		\$29-3.2	2,05	14	1.85.8	14.70
28002		Deffer (0.5	3	1.8.4.8	
		1.07(0.5	05	3.7	Q:R	De.tex
logit		23-3.2	起告	e)	+recercie	0.00
			6.3	5.4	CC: E	De.tos
logit Pojet Horses		Batate	1000	31	Que	De.to:
Tv##		03Pat.2	3.5		2.00.0	
T-WE		2049-02 2049-02	69	5	head g	
T-WE		1019-012 1019-012 1019-012	69 54X	5	T-score:	18.8
T-WE		1049413 1049412 1049412 1049413	69 54 34	5 5 5.7	Trapida Otor	rana Dr. fit
Tv##		1549-012 1549-012 1549-012 1549-012 1549-012	69 53 34 62	5 5 57 75	Тария Слан Скан	Parasi Delite Delite
Tv##	ting Sec.	District District District District District District District	69 148 1341 628 628	5 5 57 75 75	Theorem Other Other Other Other	Parasi Detite Detite Detite
Tv##	Ling Size	1954.2 1954.2 1954.2 1954.2 1954.2 1964.2 1964.2 1964.2	59 54 54 62 62 62 62	5 5 12 13 25 13	Tracinal Otor Gole Otor Dela Trata	ranaci Deuter Deuter Deuter Deuter Tamael
Tv##	ting Sec.	105412 105412 105412 105412 105412 106412 106413 106413 106413	69 53 53 62 62 62 62	5 5 17 15 15 15 0	Theoretic Once Once Once Once Theoretic	Paraci Delte Delte Delte Paraci Delte
Tv##	ting like	1954.2 1954.2 1954.2 1954.2 1954.2 1964.2 1964.2 1964.2	59 54 54 62 62 62 62	5 5 12 15 25 13	Tracinal Otor Gole Otor Dela Trata	ranaci Deuter Deuter Deuter Deuter Tamael

	@ REAC	TION	nnen kans av a al Paritye See	al ora skapert De het an stock	2,6	137	
itre .	Add New De	aice:					764
2.2	Devel:		SACTEMN .	athe o	and subjects	Land Sale	
Ade New Fatter:	Lette	-	100	1		Seator.	
Chiteria	arananye kati i	MDia	Evenenat				
lus -	Device Mana	gement:					
latifetare	Search lay: Het	cdro AVX1	1	OF February			
Courses	InD/Lator	b Drukelien	Main Site by	. Meet	Beter	Description	ii noo
LUX PL	3677981410	Robbiers	1	2	\$1.8.99	(ricent)	P.T
ad.	380010031686	Cost Neo		ND 23421 H	shutd	101,001	24
	10/19/19/10	RINAMO		latarentiyabi	Minled	300/#1	344
(m)	Distance in	llucofield			Weddenia.	2%2281	2.1
	1074939730	6000000			31.0.64	000001	Jane -
Diec:	JR1/05/91/2	KURSTRAD		RCH11140C	40203	UPUAR:	20.00
brepage	B-BITLET.	Plan.			DCR:4H	molest.	and a
	NUBBER 10	# finn:			St.Brdd	750081	2.2.
	Addition (- Million			51.6.64	34038.	into .
	_				567 11	1.17	1
Hora	Ned cation	Questionra	aites				
Ade Ken Repent				e700578939			
4 Potars	Brityn om at ' Brityn om at '			a poside webscysets ₁₀			
Ыя.	Beint ben mitt dies Die Jack Mittale fei			facts and below a			
Notifications	Man San San Man Buya Maka	THE A SHE RANGE	and the second		-	-	
Balanet:	Insuln Dig	terrate solution and the	1. Se 17	N			
tet	10 10	alt inedier ben		Medicat	ion takent		

Ealer Hen Materia

D-07211-1122-1-4

0.020307a

2028291a

COPERINGUE.

Anigy of the fire

20220100100

SWEET ROLL PONTO AULT

wg2/0.0.17#

Berritten 1.a

Ter she term

200 空日公司的edt - 2001年1 AND RATE MAN 2

0070 230Ad 122 1

CALIFORNIA stone 5

NET DIA BASE No. 7

MARTER: (1991) MONT N

Bargo Constant storm a

CROUTERHALE +

La 22 C 25 a let 7

Light.

Pice Homeset

TION	ra thuise a Oc.	scool we been	e fotwers -	1	Mary a	1
-		-	1	0		8
PORTAN		-	-	-		1
DOUGH I	od Sogar Seventi 12.1 X		inter and	G 104 0	civity Mers 1M204 Date	
1140410						
Constat	10	10				
963646	14 :41					· .
WING	AU	1F				
Bellipelat	봐 내	-				-
MINIE	12 A	율				
2008			щ			1
100000			11			23
: torain			<u>×</u>			5
DATABASE .	45					e ()
ADDARDE.	11					£
minditt	25					
Lionerite .	44					
-		-			10245-11-1	awa
174					a de Ancidia Natura	awa
120.044	Elet Questio	realm:				nun
904	- Real	nealre: nealre:	nen 1379	1331-96	int.cent	79963
ana Juctar Mar J. Toxob	Mada Research	nçidel në sazo			int.cent	in men
ticse fair	No lo Receso Co		an menaliyak ala d		ant.com	anes
ini Iotenii Iotenii Iotenii Iot	Pala Rose C	ngolel në satis Kaning or artis Chin Ali sas dh	n meni yi da i oʻ		antications), co-Cytonic (cotobie: Scolar (sector	
ana Juctar Mar J. Toxob	Pala Rose C	capitel nit casto Naceso escarto Cher Alfrico es	n meni yi da i oʻ		anti, stensi Tiros-2ytatai posti posti Biroritti	
ini Iotenii Iotenii Iotenii Iot	Polo Rose C Not were for Not in the second tense prime in Port to second	ngolel në satis Kaning or artis Chin Ali sas dh	an menaf yil din t ar n mangda lay ay 11 6	t 440 ¹¹	antications), co-Cytonic (cotobie: Scolar (sector	
ani I.:: te tele I.::::::::::::::::::::::::::::::::::::	Rolo Rome C Survey or Survey or me comparison Press or do	rapidel nik carro Romme en antie State die operatie State geschichten The antipactie free	an menaf yil din t ar n mangda lay ay 11 6	t 440 ¹¹	and a strengt	
nei Ischender Ischender Ischender	Pala Roman Co Substantia Co Su	replied to carry former of a carry char of the off in any off to carry the carry of the carry of the carry of the carry carry of the carry	n newî yê din î 1 ⁹⁷ 1- ni şiha biş er ti k 1- ni şiha biş	(1847) K	With colored Yurke-California Yorke-California Josephi	
ani I.:: te tele I.::::::::::::::::::::::::::::::::::::	As is former Co in an original former provided to the original for the second second second second second to the provided second	rapidel nit carro deserve ne artic char add car e a charagaith i na mangaith i na mangaith i na mangaith i na mangaith a d	an the saif yell after a pr ti- na tagata lay cor ± la na ar tag tag lay der der widt nach men 1	(1847) K	Infusioni Si co-Opheni Jacobie	
eni Lote hie Lote hie Cho oficino Baptec Jac	As to Renar Co Sector William Sector William Sector	ngolel ob car Roma an anti- draw de ca an Inseptible of Inseptible of Inseptible Chica and an Insection	an the saif yell after a pr ti- na tagata lay cor ± la na ar tag tag lay der der widt nach men 1	(1847) K	Extendencial Constructions and denses southers particles and any transmission and grant tra	
emi Lote falie Lot Calico Soprec Loc	Polo Remo Co Network of Polo Service Internet Press Services Company of Services Company of Services Company of Services Press Services Company of Services Press Services Company of Services	ngolel ob car Roma an anti- draw de ca an Inseptible of Inseptible of Inseptible Chica and an Insection	an menanyak aten t ar ar magtar by ar mini ar man tak by der dar weik man tak ar mel	1967 4 49 col	Extendencial Consectivities Consectivities Consectivities Description Descript	
eni Justenter Justenter Justenter Scholaren Justen Justen Justen Justen	Polo fictor C Martines (ar 1996) - Santa Santa (ar Santa) Ar Santa Ar Santa	ngolel ob car Roma an anti- draw de ca an Inseptible of Inseptible of Inseptible Chica and an Insection	e nierd die 1 2 2 might die 2	1967 4 4 9 9 9 2 2 3	Entractional Strong-Cydenial Strong-Cy	
eni Justenter Justenter Justenter Scholaren Justen Justen Justen Justen	Poloficial C acrossical C Service Services Services Services Servi	ngolel ob car Roma an anti- draw de ca an Inseptible of Inseptible of Inseptible Chica and an Insection	n neur dina a pr company er the arms dinker fere it where the fere it where the fere it was a fere it where the fere it where the fere it was a fere it where the fere fere it was a fere it was a fere fere it was a fere fere it was a fere it was a fere it was a fere fere it was a fere it was a fere it was a fere fere it was a fere it was a fere it was a fere fere it was a fere it was a fere it was a fere fere it was a fere it was a fere it was a fere it was a fere fere it was a fere it was a fere it was a fere it was a fere it was a fere fere it was a fere it was a fere it was a fere it was a fere fere it was a fere it was a fere fere it was a fere it was	1967 4 49 col	Extendencial Consectivities Consectivities Consectivities Description Descript	
eni Justenter Justenter Justenter Scholaren Justen Justen Justen Justen	Polo fictor C Martines (ar 1996) - Santa Santa (ar Santa) Ar Santa Ar Santa	ngolel ob car Roma an anti- draw de ca an Inseptible of Inseptible of Inseptible Chica and an Insection	e nierd die 1 2 2 might die 2	1 () () K () () () () () () () ()	And a growth of the second sec	
eni Justenter Justenter Justenter Scholaren Justen Justen Justen Justen	Palafic and C 	ngolel ob car Roma an anti- draw de ca an Inseptible of Inseptible of Inseptible Chica and an Insection	an heary A in a or company er the arcon the base free A rub arch and arcon the base arcon	1967 K 149 cost 146 1 8	Extension of dense souther parties and dense souther parties and gene tablegate south with souther with souther with souther and dense tablegate with souther and dense tablegate with souther and dense tablegate with souther and dense tablegate with souther and dense tablegate with souther and dense tablegate with souther and dense tablegate with souther and dense tablegate souther and dense tablegate and de	
eni Justenter Justenter Justenter Scholaren Justen Justen Justen Justen	*10 from C ************************************	ngolel ob car Roma an anti- draw de ca an Inseptible of Inseptible of Inseptible Chica and an Insection	en neur yd An d a'r L' argen hy er 214 Greu Arah wr N goori 2 9 18 18 18 18 18 18 19 29	1967 4 4 1 1 1 1 1 1 1 1 1 1 1	Windowski (* 1995) Vyce-Calabelat Vyce-Calabelat Societies Soc	
eni Justenter Justenter Justenter Scholaren Justen Justen Justen Justen	*10 from C ************************************	ngolel ob car Roma an anti- draw de ca an Inseptible of Inseptible of Inseptible Chica and an Insection	en neur yd An d a'r L' argen hy er 214 Greu Arah wr N goori 2 9 18 18 18 18 18 18 19 29	1967 4 4 1 1 1 1 1 1 1 1 1 1 1	An Angelenni Confedera contra parate Maren Mariana Maria Mariana Maria	
eni Justenter Justenter Justenter Scholaren Justen Justen Justen Justen	**************************************	ngolel ob car Roma an anti- draw de ca an Inseptible of Inseptible of Inseptible Chica and an Insection	er neuer (d. ik. d er Campitaliy er 114 an mer (d. ik. de fere d. mik mer fere 2. % 2. % 2. % 2. % 2. % 2. % 2. % 2. %	1967 K 1967 K 1968 1 1 1 1 1 1 1 1	An experiment An experiment Your Contract Former State of States and States States and States and Anne Market States States and States Stat	



- Data collection by monitoring devices (and optional manual entry of physiological data)
- Data analysis (e.g. above/below thresholds, patterns) and presentation of the results
- Integration of data from various sources
- Administrative functions (user management, equipment management, etc.)
- Data collected about diet, physical activity and medication compliance
- Generates and sends notifications (alerts, reminders) to the user
- Definition of the care plan

Sharing Information – Patient Portal







Contact number 07506 092066 / 01920 287100





- Patients can view graphical trend and tabular data
- Patients can view educational material recommended by the healthcare professionals
- Patients can manually enter physiological data and lifestyle data
- Patients can view their own care plan on patient portal
- Personalized user settings
- Decision support for patients (lifestyle advice, recommended educational resources)
- Introduction of Skype capabilities
- Ability to book appointments and order repeat prescriptions on patient portal



Measuring Outcomes

•Measure compliance as defined by Map of Medicine and NICE guidelines to identify and target interventions

•Improve patient outcomes as measured by HbA1c, Cholesterol, home blood pressure and home blood glucose measurements

- Improve patient understanding and compliance with therapeutic regimes
- Measure patient and clinical satisfaction

MAST Domains

- Clinical Outcomes
- Professional Perception
- Patient Perception
- Resource Usage and Organisational Impact



Clinical Evaluation

- Identify Risk/Risk Stratification
 - Comparative analysis of GP Judgement vs algorithm
- Measure Interventions % of whole population
- Record Types of Intervention
- Measure Compliance Levels
- Measure Time to control
- Medication Compliance



Professional Perception – Evaluation

- Clinical Portal Usability
- Device Usability
- Long Term Risk Model Usability
- ePatch Usability
- Semantic Search Usability
- Pattern Recognition Usability

W Evaluation – Measuring Project Outcomes

Patient Perception – Evaluation

- Focus Groups Nov/Dec 2013
 - Measure perception of service
 - Measure perception of tools
- Usability study of Patient Portal Dec 2013
 - 20 patients to be selected
- Questionnaires All Patients
 - Patient Perception Questionnaire

Weight State of Content of Conte

Resource and Organisational – Evaluation

- Impact on existing pathways
- Impact on clinical time
- Impact on resource usage
- Economic Reporting




Patient demographics

- 44% of population has been monitored
- Average age of subjects enrolled 65
- Average duration of diabetes 9 years
- •68% men/32% women

At baseline, patients controlled their diabetes with:

- Insulin-oral therapy combination 17%
- •Oral 49%
- Insulin 22%
- Diet and exercise 15%

(Q) Interim Results – Monitoring Statistics






- Home Gateway Black box
 - 9 patients Avg 1 hour in patient home
 - Installation by clinician and non clinical researcher
 - Selected as they had access to Broadband
- Patient Gateway
 - 87 patients
 - 8 installations by clinician Avg 45 hour in patient home
 - 79 patient self installs Avg 10 min training at health centre




- All
 - Blood Glucose Testing
- Patient Gateway
 - Mobile Connectivity
- Home Gateway (Blackbox)
 - Connectivity
 - Broken Wi-Fi Antennas
 - Installation Logistics
 - Automatic Updates

Interim Results – Clinical Outcomes Intervention Rate

Intervention rate – 24%



(Interim Results – Risk Profile







- •O% of Low Risk received an intervention
- •52% of Medium Risk received an intervention
- 100% of High Risk received an intervention

Cong Term Risk Assessment Models

- A Long Term Risk Assessment Model consists of a mathematical formula that accepts a set of parameters as input and provides an estimate of the probability of developing a particular complication
- Example: probability of Retinopathy worsening

 $p(Retinopathy) \approx -0.71 \cdot GROUP + 0.48 \cdot HBA00 + 0.25 \cdot RETPAT00$

Variables	Description
GROUP	Type of glucose control (Strict = 1,
GROUP	Normal = 0)
HBA00	Haemoglobin A1c at Baseline
RETPATO	Dating another Correction Lowel at Deceling
0	Retinopathy Severity Level at Baseline



	Probability of correctly predicting risk calculated on						
Model	DCCT sample	Type I validation cohort	Type II validation cohort				
Adverse Cardiac Event	0.7257	0.7759	0.863				
Hypoglycemia	0.6694	0.6078	-				
Ketoacidosis	0.6745	0.8824	-				
Microalbuminuria	0.7421	-	0.7288				
Proteinuria	0.833	-	-				
Neuropathy	0.6661	0.8	0.7442				
Retinopathy	0.6573	0.6635	0.4911				



- For the type I diabetes patients, 5 predictive models reached predictive performances similar to the ones obtained on the original DCCT data
 - Adverse Cardiac Event
 - Hypoglycaemia
 - Ketoacidosis
 - Neuropathy
 - Retinopathy
- The other two models did not have enough cases to provide meaningful results

Interim Results – Long Term Risk

- For Type II diabetes patients, 3 predictive models out of seven performed well on the new data
 - Adverse Cardiac Event
 - Microalbuminuria
 - Neuropathy
- The Ketoacidosis model was not applicable on Type II patients
- Not enough cases for evaluation of the models related to Hypoglycemia and Proteinuria
- The Retinopathy model provided results close to random guessing



Enhanced Care

 Provided enhanced care that was over and above what they consider to be their normal care

- More actively involved
- Improved sharing of information

Access to services

•Not helped in accessing services

Privacy and Discomfort

Most of those that agreed to take part did not have concerns

Personnel Concerns

•No concerns over who was looking at data or safety of data

Replacement for usual care

- Not a substitution for normal health
- Not as suitable as regular face to face

Satisfaction – good



- "Devices easy to use"
- "Helped monitor intake of foods"
- "Able to enter manual data when the kit did not work well"
- "Was easy to use and was helpful to see own data"
- "Made me more Proactive"
- "Tool to help me and others in the long term"
- Not a replacement for normal care "I still have diabetes and must use all resources at hand to improve my care and treatment"
- "Would like to be able to enter comments about the measurements"



• Review Visit Attendance

- Patient attendance to review visits is variable
- Some only attend once per year QOF

Blood Glucose Monitoring

- Type 2 patients not used to blood glucose monitoring

• Patient compliance to monitoring plan

 Low compliance with diet, activity and medication questionnaires – either paper based or patient portal <10 % completed to date

• Low usage of Patient Portal < 10%

- Elderly population even with access to PC there is low confidence in using
 - "Do not want to"
 - "Clinicians can look at it"
- Difficult to estimate usage
- Those that have used it report it to be useful

(Interim Results – Professional Perception

Benefits

•Helps facilitate and inform conversations with patients

Improved clinical compliance levels

- Review of clinical management
- Care plans

• "Improved ability to target those patients that need additional support which may reduce workload by not having to manage those that are not in need"

• Devices are "easy to use"

•Improvements in clinical portal are making information easier to manage but "needs to be integrated with existing EPR" to avoid duplication of data



Challenges

- Impact on workload
 - Recruitment and Traning
 - Managing incoming data Who reviews data?
 - Managing incoming data intelligent rule definitions
 - Confidence in making decisions based on incoming data
 - Increase in interventions = increase in appointments
 - Duplication of data entry EPR and REACTION Clinical Portal



Change to recruitment and training

- More targeted time spent with patient training
 - More time for patients to ask questions
 - Focus on blood glucose testing
- Reduced the need for home visits and support calls
- Less impact on clinical time
- Higher enrolment rate
- Improved home monitoring compliance

@ Patient Data Management – Rules

Alerts

- Most clinical portals provide a simple alerting system
 - Is patient data above or below defined thresholds?
- Generates alerts on a screen
- Many tend to be false alerts
 - Time consuming to review data
 - Clinicians begin to ignore
- •Systems need to be based on clinical workflow
 - Monitoring of Acute Exacerbations
 - Monitoring of Trend

Oracle Patient Data Management – Basic Rules

Use Case 1:

•Is physiological data from the devices being received each day? – or is there missing data?

• If data is not being received the device status should be checked for connectivity issues and the patient should be contacted by phone to determine if there is a reason for the missing physiological data. Reasons for missing data

- Patient forgot or did not want to take a measurement
- Patient Training issue
- Device error
- Transmission error
- Clinical Web Server Error

Oracle Patient Data Management – Basic Rules

Use Case 2:

• Is the physiological data extreme? – e.g. blood glucose < 4 or > than 14 AND/ OR Blood Pressure < 90/10 OR > 210/110

• If the physiological data is an extreme value the clinician will make a clinical judgement as to whether they should contact the patient or continue to monitor. Reasons for extreme values could include:

- Device error
- Patient training issue
- Clinical reason
- Transmission error
- Clinical Web Server Error



Use Case 3:

• It is found that the patients' Blood Glucose levels are too high, the patient has previously had medication which has made them have hypos. Patient is prescribed an additional medication. Clinician wants to monitor their BP and BG for 1 month

- Extreme values
- Missing values
- Is the average blood glucose of 14 days > 7 mmol/L
- Is the average blood pressure of 14 days => 140/80 OR
- Does the patient have a history of kidney, eye, cardiovascular AND is the average blood pressure of 14 days > 130/80



- Clinical Evaluation January 2014
- Integration of data with EPR talks with EPR provider
- Improved data analysis and information visualization methods
- Advanced patient management and notification
- Integration of
- Semantic search
- Long Term Risk Tool into clinical portal



Aim

•To investigate the usefulness and feasibility of using the ePatch[®] in a Primary Care setting from a clinician's perspective

•To understand the usability and satisfaction from a patient's perspective

Methods

•5 patients who attend the Warfarin clinic at Chorleywood Health Centre were invited to take part in the demonstration




- The ePatch[®] fitted to patient and asked to wear for 24 hours
- Patient instructed not to shower or get the sensor wet while wearing it
- Patients asked to return to the health centre the next day to have the sensor removed
- Patients asked to complete a questionnaire









pt1005 – woken up at 4:30 am by two cats in bed













- All of the patients said the ePatch[®] was very comfortable to wear
 - "Don't know I've got it on, especially in bed. I have had boxes and in bed they are very uncomfortable"
 - "Unaware of wearing it"
- All patients said that they felt the ePatch[®] was very discreet
 - "The ePatch would be very obvious if worn with an open top neckline"
 - "Possibly it being so unobtrusive you can forget you've got it on e.2. Buttoning up shirt and putting clothes over the head"
 - "Unnoticeable"
- None of the patients reported any problems while wearing the ePatch[®]
- All of the patients were very satisfied with the ePatch[®]